Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int. 2021;15(3):663–75

Article  PubMed  Google Scholar 

Lim J, Kim KW, Ko Y, Jang IY, Lee YS, Chung YH, et al. The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE. BMC Cancer. 2021;21(1):1164

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mosconi C, Gramenzi A, Biselli M, Cappelli A, Bruno A, De Benedittis C, et al. Survival and tolerability of transarterial chemoembolization in greater versus less than 70 years of age patients with unresectable hepatocellular carcinoma: a propensity score analysis. Cardiovasc Intervent Radiol. 2020;43(7):1015–24

Article  PubMed  Google Scholar 

Li D, Liu S, Cheng C, Xu L, Zhao P. Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2023;102(35): e34811

Article  CAS  PubMed  Google Scholar